Treatment of bullous pemphigoid with adjuvant immunoadsorption: A case series

2014 ◽  
Vol 71 (5) ◽  
pp. 1018-1020 ◽  
Author(s):  
Michael Kasperkiewicz ◽  
Franziska Schulze ◽  
Markus Meier ◽  
Nina van Beek ◽  
Martin Nitschke ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Case Series

scholarly journals Bullous Pemphigoid Associated with Multiple System Atrophy: Case Series

2021 ◽  
Author(s):  
Andrew Snedden ◽  
Jennifer Sharif ◽  
John Newsham ◽  
Christopher Kobylecki
Keyword(s):  
Multiple System Atrophy ◽  
Bullous Pemphigoid ◽  
Case Series

scholarly journals Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid

2021 ◽  
Vol 10 (9) ◽  
pp. 1916
Author(s):  
Ágnes Kinyó ◽  
Anita Hanyecz ◽  
Zsuzsanna Lengyel ◽  
Dalma Várszegi ◽  
Péter Oláh ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Clinical Laboratory ◽  
Case Series ◽  
Dipeptidyl Peptidase ◽  
Area Index ◽  
Histological Features ◽  
Dipeptidyl Peptidase 4 ◽  
First Case ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
The Mean

Bullous pemphigoid (BP) is an autoimmune blistering disease of elderly patients that has shown increasing incidence in the last decades. Higher prevalence of BP may be due to more frequent use of provoking agents, such as antidiabetic dipeptidyl peptidase-4 inhibitor (DPP4i) drugs. Our aim was to assess DPP4i-induced bullous pemphigoid among our BP patients and characterize the clinical, laboratory and histological features of this drug-induced disease form. In our patient cohort, out of 127 BP patients (79 females (62.2%), 48 males (37.7%)), 14 (9 females and 5 males) were treated with DPP4i at the time of BP diagnosis. The Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema score was significantly lower, and the BPDAI damage score was significantly higher in DPP4i-BP patients compared to the nonDPP4i group. Both the mean absolute eosinophil number and the mean periblister eosinophil number was significantly lower in DPP4i-BP patients than in nonDPP4i cases (317.7 ± 0.204 vs. 894.0 ± 1.171 cells/μL, p < 0.0001; 6.75 ± 1.72 vs. 19.09 ± 3.1, p = 0.0012, respectively). Our results provide further evidence that DPP4i-associated BP differs significantly from classical BP, and presents with less distributed skin symptoms, mild erythema, normal or slightly elevated peripheral eosinophil count, and lower titers of BP180 autoantibodies. To our knowledge, this is the first case series of DPP4i-related BP with a non-inflammatory phenotype in European patients.

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series

2020 ◽  
Vol 83 (1) ◽  
pp. 46-52 ◽  
Author(s):  
Rana Abdat ◽  
Reid A. Waldman ◽  
Valeria de Bedout ◽  
Annette Czernik ◽  
Michael Mcleod ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Case Series ◽  
Novel Therapy

scholarly journals Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey

Renal Failure ◽  
2021 ◽  
Vol 43 (1) ◽  
pp. 651-657
Author(s):  
Kohkichi Morimoto ◽  
Tadashi Yoshida ◽  
Naoki Washida ◽  
Kiyotaka Uchiyama ◽  
Takashin Nakayama ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Bullous Pemphigoid ◽  
Case Series ◽  
Literature Survey

Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients

2020 ◽  
pp. 120347542097234
Author(s):  
Miriam Armanious ◽  
Mohn’d AbuHilal
Keyword(s):  
Bullous Pemphigoid ◽  
Case Series ◽  
Rapid Improvement ◽  
Drug Induced ◽  
Dipeptidyl Peptidase 4 ◽  
Early Withdrawal ◽  
Immune Mediated ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Causative Agents

Background Bullous pemphigoid (BP) is a chronic immune-mediated vesiculobullous disorder. Recently, several reports have described dipeptidyl peptidase-4 inhibitors, also known as gliptins, as causative agents for drug-induced BP. Objective To report and describe clinical and histologic characteristics of 10 cases of gliptin-induced BP. Results We identified 10 patients with gliptin-induced BP. Nine were secondary to linagliptin, and 1 case was attributed to sitagliptin. All patients showed significant improvement after withdrawal of gliptin medications and proper medical treatment. There has been no evidence of relapse after 4 months of follow-up. Conclusion This report supports the proposed association between gliptins and BP. Physicians should be aware of this potential adverse effect, as gliptin-induced BP can be reversible once identified and the responsible medication is stopped. Early withdrawal of the offending drug and proper treatment can lead to rapid improvement and reduced morbidity.

scholarly journals Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Yotsapon Thewjitcharoen ◽  
Ekgaluck Wanothayaroj ◽  
Chattip Thammawiwat ◽  
Sriurai Porramatikul ◽  
Chuleekorn Vorayingyong ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Case Series ◽  
Latency Period ◽  
Dipeptidyl Peptidase ◽  
Elderly Male ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Potential Link ◽  
Male Patients

The use of dipeptidyl peptidase-4 inhibitors (DPP4i) appears to be associated with a small but significantly elevated risk of bullous pemphigoid (BP). Although the pathogenic mechanism of DPP4i-associated BP remains unclear, this adverse event is reported with multiple gliptins, suggesting a class effect. However, previous studies from various countries showed that vildagliptin had been implicated in most cases. The aim of this study was to illustrate a case series of DPP4i-associated BP in Thai patients. We conducted a retrospective study from consecutive cases of BP in people with type 2 diabetes mellitus (T2DM) from January 2008, the year in which the first DPP4i was introduced in Thailand, until December 2019. During the study period, 10 BP patients with T2DM were identified. A total of 5 DPP4i-associated BP (3 on vildagliptin, 1 on linagliptin, and 1 on sitagliptin) were found. All patients were male with a mean age at BP development of 80.4 years (73–86 years). All patients had a long-standing duration of diabetes (median duration 34 years), and mean A1C was 7.5 ± 1.4%. The median time to BP development after the introduction of DPP4i was 64 months (range 20–128 months). The severity of BP was classified as mild in 2 cases. In all cases, the association between the drug intake and BP onset was classified as “possible” according to the Naranjo causality scale. All of the patients continued taking DPP4i after BP diagnosis, and one patient died of lung cancer 18 months after BP diagnosis. Only 2 patients could achieve complete remission at least 2 months after stopping DPP4i. Our case series demonstrated a potential link between DPP4i and the development of BP, which mainly occurred in very elderly male patients. The latency period from an introduction of DPP-4i could be several years, and the clinical course after DPP4i discontinuation varied. Clinicians prescribing DPP4i should be aware of this association and consider stopping this medication before a refractory disease course ensues.

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database

2019 ◽  
Vol 59 (2) ◽  
pp. 197-206 ◽  
Author(s):  
Alejandra Reolid ◽  
Ester Muñoz‐Aceituno ◽  
Pedro Rodríguez‐Jiménez ◽  
Esperanza González‐Rojano ◽  
Mar Llamas‐Velasco ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Case Series ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Pharmacovigilance Database ◽  
Analysis Of Cases

scholarly journals Bullous pemphigoid and radiotherapy: case report and literature review update

2021 ◽  
Author(s):  
Antonio Piras ◽  
Bruno Fionda ◽  
Antonella Sanfratello ◽  
Andrea D'Aviero ◽  
Giovanni Sortino ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Large Scale ◽  
Case Reports ◽  
Normal Skin ◽  
Disease Onset ◽  
Case Series ◽  
Characteristics Analysis ◽  
Meta Analyses

INTROUDCTION Bullous pemphigoid (BP) is a common autoimmune bullous disease generally occurring in elderly patients. Itchy and tense blisters on normal skin or erythematous and edematous lesions on the trunk and extremities usually characterize BP. Trigger factors are still unclear while several case reports suggest a potential role of radiotherapy (RT) as BP trigger for disease onset or recrudescence. A review was performed in order to provide an update of literature. A case report of a patient affected by BP undergoing two radiotherapy courses for a primary breast cancer was also reported. MATERIALS AND METHODS A comprehensive review of the published literature was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. The review included studies describing BP and its relationships with RT treatments. RESULTS A total of 13 articles were reviewed. Studies characteristics analysis resulted in eleven case reports, one case series and one large-scale case–control study. CONCLUSIONS Literature update confirms the existence of a reasonable connection between RT and BP. Case report showed that a multidisciplinary management seems to assure the feasibility of RT in patients affected by BP, not depriving them of standard therapeutic opportunities.

Sign in / Sign up

Export Citation Format

Share Document